UNSPSC 51422342: Dexamethasone sodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI9376Y64P, chemically known as 16-alpha-methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione but more generally known as dexamethasone sodium phosphate, which bears US NIH Compound Identifier 5743. European Medicines Agency schedules Dexamethasone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01615MIG.

UNSPSC 51422342 Dexamethasone sodium phosphate (Commodity tier) describes a specific pharmaceutical agent, but recent state and local activity under this code shows a significant mismatch: the two posted opportunities involve naloxone procurement and direct-to-manufacturer pharmacy benefit management initiatives, neither of which involve dexamethasone sodium phosphate. The code shows little relevant recent activity aligned with its nominal scope; state and local procurement officers appear to be tagging broader pharmaceutical and drug-management solicitations under this code without specificity to the dexamethasone product itself.

Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, posted June 30, 2026, due July 26, 2023) for naloxone and safe drug deactivation systems with quarterly deliveries to its Community Health Building in Sanford, while the Texas Health and Human Services Commission released an RFI (HHS0017013, posted April 3, 2026, due April 3, 2026) exploring direct-to-manufacturer prescription programs and pharmacy benefit contracting models. Neither solicitation purchases dexamethasone sodium phosphate specifically. The code's recent posting activity is concentrated in the Southeast and South, but the pharmaceutical products actually being procured fall outside the code's stated commodity scope, suggesting either miscoding at source or use of the code as a catch-all for drug-related procurement. Vendors should verify actual product requirements in solicitation detail rather than assuming alignment between the UNSPSC number and deliverables.